LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) promoted Yasmine Wasfi, M.D., Ph.D., FCCP, to chief medical officer, succeeding Ray Pratt, M.D., FACP, who will become senior medical advisor. Wasfi, formerly executive vice president and head of clinical development and clinical operations, will report to the chair and chief executive officer and join the executive leadership team.
“We are pleased to promote Dr. Wasfi to CMO,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Dr. Wasfi is a pulmonologist with more than two decades of healthcare experience, spanning both biotech and large pharma. She has a strong track record progressing and driving the development strategy for investigational therapies within the respiratory and immunology therapeutic areas and her leadership and relentless commitment to the autoimmune pulmonary alveolar proteinosis, or autoimmune PAP, patient community has been instrumental in helping advance the MOLBREEVI* program. We appreciate Dr. Wasfi’s contributions to date and look forward to the insights and direction she will bring in her new role.”
Pauls added: “Having contributed to many regulatory applications over the span of his 35 years in drug development, we are grateful to benefit from Dr. Pratt’s experience and thank him for his invaluable contributions in advancing the MOLBREEVI program. We are fortunate to continue with his guidance as a Senior Medical Advisor.”
“I’d like to congratulate Dr. Wasfi on her promotion,” said Ray Pratt, M.D., FACP, CMO, Savara. “She brings significant experience in biopharmaceuticals to this role and has already made important contributions to our clinical development and regulatory efforts. It’s been a privilege to lead the MOLBREEVI clinical program through numerous late-stage milestones as we work to bring the first and only approved therapy for autoimmune PAP to market in the U.S. and Europe. I look forward to continue supporting the Company in my role as Senior Medical Advisor.”
Savara said Wasfi’s background spans large and small molecule programs in respiratory and late-phase immunology. Her prior roles include leadership positions at Amicus Therapeutics, Johnson & Johnson, and Merck. She holds a B.A. in biology from the University of Delaware, an M.D. from the University of Pennsylvania School of Medicine, and a Ph.D. in clinical science from the University of Colorado Health Sciences Center, where she also completed a fellowship in Pulmonary and Critical Care.
The company continues to advance MOLBREEVI for autoimmune pulmonary alveolar proteinosis, citing growing organizational focus on rare lung diseases and the need to fortify late-stage development and regulatory execution with stable leadership.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.